Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 3
2000 3
2001 1
2002 8
2003 19
2004 31
2005 38
2006 58
2007 46
2008 75
2009 78
2010 105
2011 133
2012 140
2013 174
2014 210
2015 254
2016 238
2017 231
2018 250
2019 253
2020 295
2021 339
2022 296
2023 37
Text availability
Article attribute
Article type
Publication date

Search Results

2,906 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Lim J, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, Lee HC, Choi J. Lim J, et al. Liver Int. 2022 Jul;42(7):1517-1527. doi: 10.1111/liv.15261. Epub 2022 Apr 3. Liver Int. 2022. PMID: 35343041
BACKGROUND AND AIMS: We used real-world data to evaluate the efficacy and safety of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in treatment-naive patients with CHB. ...
BACKGROUND AND AIMS: We used real-world data to evaluate the efficacy and safety of tenofovir alafenamide (TAF) compared with teno …
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Chon HY, Ahn SH, Kim YJ, Yoon JH, Lee JH, Sinn DH, Kim SU. Chon HY, et al. Hepatol Int. 2021 Dec;15(6):1328-1336. doi: 10.1007/s12072-021-10262-y. Epub 2021 Nov 20. Hepatol Int. 2021. PMID: 34799838
BACKGROUND AND AIMS: Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development. The outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) were compared in patients …
BACKGROUND AND AIMS: Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development. T …
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Han Y, Zeng A, Liao H, Liu Y, Chen Y, Ding H. Han Y, et al. Int Immunopharmacol. 2017 Jan;42:168-175. doi: 10.1016/j.intimp.2016.11.022. Epub 2016 Dec 1. Int Immunopharmacol. 2017. PMID: 27915131 Review.
BACKGROUND: The purpose of this study was to assess the efficacy and safety between tenofovir and entecavir in the treatment of CHB and HBV related cirrhosis through Meta-analysis. Methods The electronic databases of PubMed, the Cochrane Library, Nature, CNKI and WanFang d …
BACKGROUND: The purpose of this study was to assess the efficacy and safety between tenofovir and entecavir in the treatment of CHB a …
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. Agarwal K, et al. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. J Hepatol. 2018. PMID: 29756595 Clinical Trial.
BACKGROUND & AIMS: Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of t …
BACKGROUND & AIMS: Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic h …
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Tseng CH, et al. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30. Lancet Gastroenterol Hepatol. 2020. PMID: 33007228
BACKGROUND: It is unclear whether tenofovir disoproxil fumarate and entecavir differ in their association with risk of hepatocellular carcinoma in patients with chronic hepatitis B, and previous meta-analyses have shown conflicting conclusions with substantial heter …
BACKGROUND: It is unclear whether tenofovir disoproxil fumarate and entecavir differ in their association with risk of hepatocellular …
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.
Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Jourdain G, et al. N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131. N Engl J Med. 2018. PMID: 29514030 Free PMC article. Clinical Trial.
BACKGROUND: Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin. ...Infants received hepatitis B immune globulin at birth and …
BACKGROUND: Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infa …
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, Chou R, Bulterys M, Shimakawa Y. Funk AL, et al. Lancet Infect Dis. 2021 Jan;21(1):70-84. doi: 10.1016/S1473-3099(20)30586-7. Epub 2020 Aug 14. Lancet Infect Dis. 2021. PMID: 32805200 Free article.
The pooled ORs for randomised controlled trials were similar, at 0.10 (95% CI 0.03-0.35) for tenofovir disoproxil fumarate, 0.16 (0.10-0.26) for lamivudine, and 0.14 (0.09-0.21) for telbivudine. The pooled ORs in non-randomised studies were 0.17 (0.10-0.29) for tenofovi …
The pooled ORs for randomised controlled trials were similar, at 0.10 (95% CI 0.03-0.35) for tenofovir disoproxil fumarate, 0.16 (0.1 …
Treatment and prevention of viral hepatitis in pregnancy.
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Dionne-Odom J, et al. Am J Obstet Gynecol. 2022 Mar;226(3):335-346. doi: 10.1016/j.ajog.2021.09.002. Epub 2021 Sep 10. Am J Obstet Gynecol. 2022. PMID: 34516961 Review.
The route of infection varies widely and ranges from fecal-oral transmission for the hepatitis A and E viruses to vertical transmission for hepatitis B, blood-borne transmission for hepatitis C, and sexual transmission for the herpes simplex virus. ...Antivir …
The route of infection varies widely and ranges from fecal-oral transmission for the hepatitis A and E viruses to vertical transmissi …
Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Yang X, Yan H, Zhang X, Qin X, Guo P. Yang X, et al. Int J Infect Dis. 2022 Nov;124:133-142. doi: 10.1016/j.ijid.2022.09.021. Epub 2022 Sep 16. Int J Infect Dis. 2022. PMID: 36122671 Free article. Review.
OBJECTIVES: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as first-line treatments for chronic hepatitis B (CHB). ...METHODS: The electronic databases of the Cochrane Library, PubMed, and Embase were searched. The keywords were: "CHB", " …
OBJECTIVES: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as first-line treatments for chronic hepatitis …
Comparison of tenofovir alafenamide and entecavir for hepatitis B virus-related acute-on-chronic liver failure.
Peng W, Gu H, Jiang C, Liu J, Zhang J, Fu L. Peng W, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Feb 28;47(2):194-201. doi: 10.11817/j.issn.1672-7347.2022.210578. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35545409 Free article. Chinese, English.
OBJECTIVES: Hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is the most common type of liver failure in China, with a high mortality. ...At present, the commonly used drugs are nucleoside (acid) analogues, such as entecavir (ETV), tenofovir, and …
OBJECTIVES: Hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is the most common type of liver failure in China, wi …
2,906 results